How to: Measuring blood cytokines in biological psychiatry using commercially available multiplex immunoassays

Abstract

Cytokines produced by both immune and non-immune cells are likely to play roles in the development and/or progression of psychiatric disorders. Indeed, many investigators have compared the blood cytokine levels in psychiatric patients with those of healthy controls or monitored their levels in patients during disease progression to identify biomarkers. Nevertheless, very few studies have confirmed that such cytokines remain stable in healthy individuals through periods of weeks and months. This is an important issue to consider before using blood cytokine levels as biomarkers of disease traits, disease state, or treatment response. Although multiplex assay technology represents an advance in identifying biomarkers because it allows simultaneous examination of large panels of analytes from a small volume of sample, it is necessary to verify whether these assays yield enough sensitivity and reproducibility when applied to the blood from neuropsychiatric patients. Therefore, we compared two multiplex immunoassays, the bead-based Luminex® (Bio-Rad) and the electro-chemiluminescence-based V-plex® (MesoScaleDiscovery), for the detection and quantification of 31 cytokines, chemokines and growth factors in both the sera and plasma of patients with major depressive episodes (MDE) and age-and sex-matched healthy control subjects during a 30-week period. Although both platforms exhibited low coefficients of variability (CV) between the duplicates in the calibration curves, the linearity was better in general for the V-PLEX® platform. However, neither platform was able to detect the absolute values for all of the tested analytes. Among the 16 analytes that were detected by both assays, the intra-assay reproducibility was in general better with the V-PLEX® platform. Although it is not a general rule that the results from sera and plasma will be correlated, consistent results were more frequent with the V-PLEX® platform. Furthermore, the V-PLEX® results were more consistent with the gold standard ELISA simplex assay for IL-6 in both sera and plasma. The intra-individual variability of the measurements, among the sera and plasma for the 4 samples harvested from each healthy individual, was low for Eotaxin, G-CSF, IL-4, IL-7, IL-9, IL-12p40, IL-12p70, IL-15, MIP-1β, PDGF-BB, TNF, TNF-β and VEGF, but intermediate or high for IFN-γ, IL-6, IL-8, IL-10, and IP10. Together, these data suggest that extreme caution is needed in translating the results of multiplex cytokine profiling into biomarker discovery in psychiatry. Dear Editor,We thank you and the Editor in chief, Robert Dantzer, for reaching the conclusion to ultimately publish our manuscript. Following your suggestion, we changed the tiltle to: "How to: Measuring blood cytokines in biological psychiatry using commercially available multiplex immunoassays".We were concerned by the persistent negative comments of Reviewer#3, stressing out that our comparison between the two platforms we have worked with suffers a number of theoretical and technical limitations because...

Serum thyroid-stimulating hormone and interleukin-8 levels in boys with autism spectrum disorder

“…We sought to replicate the serum biomarker proteins identified on the RBM platform by subsequently analyzing proteins on a Meso Scales Discovery (MSD) platform [19] run in-house. Compared with the traditional ELISA approach, the MSD platform shows greater sensitivity and is able to reliably detect different proteins across a broad dynamic range of concentrations [20].…”

Aerobic Exercise Attenuates Acute Lung Injury Through NET Inhibition

“…The BALF and cell culture supernatant levels of IL-1β, IL-6, IL-10, and TNF-α were analyzed using the Bio-Plex Pro Mouse Cytokine 6-plex Assay (Bio-Rad, product No. M6000007NY) according to the manufacturer's instructions in the Bio-Plex 200 system (Bio-Rad, Hercules, CA) as previously reported (15).…”

Proteomic Profiling as a Diagnostic Biomarker for Discriminating Between Bipolar and Unipolar Depression

“…Furthermore, PDGF-BB was found to be increased in BD patients suffering a depressive episode after treatment with a combination of sleep deprivation, lithium and bright light therapy (29). PDGF-BB was also found to have low intraindividual variability when measured with different methods and in serum and plasma, suggesting that this marker may be technically reliable (30). Physiologically, PDGF receptors have been reported to play a role in glutamatergic signaling (31), which is thought to be dysregulated in subtypes of affective patients (32).…”